Zhao, Mingye; Jiang, Yunlin; Shao, Taihang; Tang, Wenxi - 2025
Objectives To conduct pooled estimates and comparative evaluations of safety and efficacy, alongside cost-effectiveness …-BEV had the greatest PFS and OS survival benefit, followed by fruquintinib and REDo. Cost-effectiveness analysis favored BSC … as the least expensive and the most cost-effective profile. TAS-BEV had the greatest effectiveness, with TAS-102 being …